Top

Published in:

01-05-2006 | Original Paper

Complement Activation Is Involved in Biological Responses to Leukocyte Adsorptive Apheresis

Authors: Shoichi Nishise, Yuji Takeda, Hiroaki Takeda, Katsuyoshi Ishihama, Tadahisa Fukui, Sumio Kawata

Published in: Digestive Diseases and Sciences | Issue 5/2006

Abstract

We examined the effects of complement activation on the biological responses of cellulose acetate (CA) beads. Peripheral blood containing the complement activation inhibitor nafamostat mesilate (NM) or heparin was incubated with CA beads in vitro. Thereafter, the fraction of adsorbed granulocytes as well as the generation of complement activation fragments (C3a and C5a) and interleukin 1 receptor antagonist (IL-1ra) were measured. Granulocyte adsorption, complement activation, and IL-1ra release were significantly inhibited in the presence of NM. Adsorption was significantly increased onto CA beads pretreated with plasma containing heparin even in the presence of NM and adding C3a or C5a enhanced IL-1ra release. These results suggested that bound complement fragment (e.g., C3b) on CA beads plays a central role in granulocyte adsorption to CA beads and that C3a and C5a augment the release of anti-inflammatory substances. We therefore conclude that complement activation is involved in these biological responses of leukocyte apheresis.

Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Matsueda K, Munakata A, Asakura H, Tanaka T, Kasukawa R, Kimura K, Suzuki Y, Nagamachi Y, Muto T, Nagawa H, Iizuka B, Baba S, Nasu M, Kataoka T, Kashiwagi N, Saniabadi AR (2001) Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apheresis 16:1–9PubMedCrossRef

Hay FC, Nineham LJ, Perumal R, Roitt IM (1979) Intra-articular and circulating immune complexes and antiglobulins (IgG and IgM) in rheumatoid arthritis; correlation with clinical features. Ann Rheum Dis 38:1–7PubMed

Edwards SW, Hallett MB (1997) Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol Today 18:320–324PubMedCrossRef

Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115:182–205PubMedCrossRef

Ohara M, Saniabadi AR, Kokuma S, Hirata I, Adachi M, Agishi T, Kasukawa R (1997) Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif Organs 21:989–994PubMed

Hanai H, Watanabe F, Saniabadi AR, Matsushitai I, Takeuchi K, Iida T (2002) Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci 47:2349–2353PubMedCrossRef

Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, Saniabadi A, Matsushita I, Sato Y, Tozawa K, Arai H, Furuta T, Sugimoto K, Bjarnason I (2003) Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 1:28–35PubMedCrossRef

Takeda Y, Hiraishi K, Takeda H, Shiobara N, Shibusawa H, Saniabadi AR, Adachi M, Kawata S (2003) Cellulose acetate beads induce release of interleukin-1 receptor antagonist, but not tumour necrosis factor-α or interleukin-1β in human peripheral blood. Inflamm Res 52:287–290PubMed

Saniabadi AR, Hanai H, Takeuchi K, Umemura K, Adachi T, Shima C, Bjarnason I, Lofberg R (2003) Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 7:48–59PubMedCrossRef

10.

Takeda Y, Shiobara N, Saniabadi AR, Adachi M, Hiraishi K (2004) Adhesion dependent release of hepatocyte growth factor and interleukin-1 receptor antagonist from human blood granulocytes and monocytes: evidence for the involvement of plasma IgG, complement C3 and β2 integrin. Inflamm Res 53:277–283PubMedCrossRef

11.

Arend WP, Malyak M, Guthridge CJ, Gabay C (1998) Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 16:27–55PubMedCrossRef

12.

Tahara Y, Ido A, Yamamoto S, Miyata Y, Uto H, Hori T, Hayashi K, Tsubouchi H (2003) Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats. J Pharmacol Exp Ther 307:146–151PubMedCrossRef

13.

Hoenich NA, Woffindin C, Matthews JN, Goldfinch ME, Turnbull J (1994) Clinical comparison of high-flux cellulose acetate and synthetic membranes. Nephrol Dial Transplant 9:60–66PubMed

14.

Matata BM, Yin HQ, Courtney JM, Gaylor JD, Lamba NM, Lowe GD, Suzuki K, Kimura H, Izumi K, Klinkmann H (1996) In vitro blood compatibility evaluation of hollow fibre membrane using a controlled flow system: a comparative study. Int J Artif Organs 19:582–589PubMed

15.

Ivanovich P, Chenoweth DE, Schmidt R, Klinkmann H, Boxer LA, Jacob HS, Hammerschmidt DE (1984) Cellulose acetate hemodialysis membranes are better tolerated than Cuprophan. A difference in complement and neutrophil activation. Contrib Nephrol 37:78–82PubMed

16.

Hiraishi K, Takeda Y, Shiobara N, Shibusawa H, Jimma F, Kashiwagi N, Saniabadi AR, Adachi M (2003) Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 7:334–340PubMedCrossRef

17.

Hartmann K, Henz BM, Kruger-Krasagakes S, Kohl J, Burger R, Guhl S, Haase I, Lippert U, Zuberbier T (1997) C3a and C5a stimulate chemotaxis of human mast cells. Blood 89:2863–2870PubMed

18.

Stove S, Welte T, Wagner TOF, Kola A, Klos A, Bautsch W, Kohl J (1996) Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome. Clin Diagn Lab Immunol 3:175–183PubMed

19.

Bjork J, Hugli TE, Smedegard G (1985) Microvascular effects of anaphylatoxins C3a and C5a. J Immunol 134:1115–1119PubMed

20.

Vogt W (1986) Anaphylatoxins: possible roles in disease. Complement 3:177–188PubMed

21.

Belmont HM, Hopkins P, Edelson HS, Kaplan HB, Ludewig R, Weissmann G, Abramson S (1986) Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arth Rheum 29:1085–1089

22.

Strey CW, Markiewski M, Mastellos D, Tudoran R, Spruce LA, Greenbaum LE, Lambris JD (2003) The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med 198:913–923PubMedCrossRef

23.

Rousseau Y, Haeffner-Cavaillon N, Poignet JL, Meyrier A, Carreno MP (2000) In vivo intracellular cytokine production by leukocytes during haemodialysis. Cytokine 12:506–517PubMedCrossRef

24.

Aoyama T, Ino Y, Ozeki M, Oda M, Sato T, Koshiyama Y, Suzuki S, Fujita M (1984) Pharmacological studies of FUT–175, nafamostat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 35:203–227PubMed

25.

Ikari N, Sakai Y, Hitomi Y, Fujii S (1983) New synthetic inhibitor to the alternative complement pathway. Immunology 49:685–691PubMed

26.

Beijering RJ, ten Cate H, Nurmohamed MT, ten Cate JW (1997) Anticoagulants and extracorporeal circuits. Semin Thromb Hemost 23:225–233PubMedCrossRef

27.

Takahashi H, Muto S, Nakazawa E, Yanagiba S, Masunaga Y, Miyata Y, Tamba K, Kusano E, Matsuo M, Matsuo T, Asano Y (2003) Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced thrombocytopenia in a hemodialysis patient. Clin Nephrol 59:458–462PubMed

28.

Kashiwagi N, Sugimura K, Koiwai H, Yamamoto H, Yoshikawa T, Saniabadi AR, Adachi M, Shimoyama T (2002) Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 47:1334–1341PubMedCrossRef

29.

Pfeifer PH, Kawahara MS, Hugli TE (1999) Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin Chem 45:1190–1199PubMed

30.

Ezekowitz RAB, Hoffmann JA (1998) Innate immunity. Curr Opin Immunol 10:9–11CrossRef

31.

Tack BF, Harrison RA, Janatova J, Thomas ML, Prahl JW (1980) Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci USA 77:5764–5768PubMedCrossRef

32.

Law SK, Levine RP (1977) Interaction between the third complement protein and cell surface macromolecules. Proc Natl Acad Sci USA 74:2701–2705PubMedCrossRef

33.

Kolb WP, Morrow PR, Tamerius JD (1989) Ba and Bb fragments of factor B activation: fragment production, biological activities, neoepitope expression and quantitation in clinical samples. Complement Inflamm 6:175–204PubMed

34.

Volanakis JE (1990) Participation of C3 and its ligands in complement activation. Curr Top Microbiol Immunol 153:1–21PubMed

35.

Ueda M, Deguchi M, Takemura S, Kasamatsu Y, Yanagida K, Fukuda W, Okamoto M, Onodera H, Sugino S, Kondo M (1991) The relationship between complement C3 receptors (CR1, CR3) on polymorphonuclear leukocytes and complement fragments during hemodialysis. Nippon Jinzo Gakkai Shi 33:679–684 (in Japanese with English abstract)PubMed

36.

Webster RO, Larsen GL, Henson PM (1982) In vivo clearance and tissue distribution of C5a and C5a des arginine complement fragments in rabbits. J Clin Invest 70:1177–1183PubMedCrossRef

37.

Nakae H, Tajimi K (2003) Pharmacokinetics of nafamostat mesilate during continuous hemodiafiltration with a polyacrylonitrile membrane. Ther Apher Dial 7:483–485PubMedCrossRef

Title: Complement Activation Is Involved in Biological Responses to Leukocyte Adsorptive Apheresis
Authors: Shoichi Nishise
Yuji Takeda
Hiroaki Takeda
Katsuyoshi Ishihama
Tadahisa Fukui
Sumio Kawata
Publication date: 01-05-2006
Publisher: Kluwer Academic Publishers-Plenum Publishers
Published in: Digestive Diseases and Sciences / Issue 5/2006
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-005-9050-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2006

Alkaline Phosphatase Predicts Survival in Patients with Metastatic Neuroendocrine Tumors

ERRATUM

The Incidence of Irritable Bowel Syndrome Among Community Subjects With Previous Acute Enteric Infection

Low Plasma Nitrite in Infantile Hypertrophic Pyloric Stenosis Patients

Results of Videocapsule Endoscopy &#x220A; 250 Patients With Suspected Small Bowel Pathology

Celiac Disease in African-Americans

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials

Results of Videocapsule Endoscopy ∊ 250 Patients With Suspected Small Bowel Pathology